Literature DB >> 9715377

The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity.

J E Gerich1.   

Abstract

Despite the fact that it is the prevalent view that insulin resistance is the main genetic factor predisposing to development of type 2 diabetes, review of several lines of evidence in the literature indicates a lack of overwhelming support for this concept. In fact, the literature better supports the case of impaired insulin secretion being the initial and main genetic factor predisposing to type 2 diabetes, especially 1) the studies in people at high risk to subsequently develop type 2 diabetes (discordant monozygotic twins and women with previous gestational diabetes), 2) the studies demonstrating compete alleviation of insulin resistance with weight loss, and 3) the studies finding that people with type 2 diabetes or IGT can have impaired insulin secretion and no insulin resistance compared with well matched NGT subjects. The fact that insulin resistance may be largely an acquired problem in no way lessens its importance in the pathogenesis of type 2 diabetes. Life style changes (exercise, weight reduction) and pharmacological agents (e.g., biguanides and thiazolidendiones) that reduce insulin resistance or increase insulin sensitivity clearly have major beneficial effects (122, 144-146, 153-155).

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9715377     DOI: 10.1210/edrv.19.4.0338

Source DB:  PubMed          Journal:  Endocr Rev        ISSN: 0163-769X            Impact factor:   19.871


  79 in total

Review 1.  Defining the genetic contribution of type 2 diabetes mellitus.

Authors:  J van Tilburg; T W van Haeften; P Pearson; C Wijmenga
Journal:  J Med Genet       Date:  2001-09       Impact factor: 6.318

2.  History of diabetes and risk of head and neck cancer: a pooled analysis from the international head and neck cancer epidemiology consortium.

Authors:  Marni Stott-Miller; Chu Chen; Shu-Chun Chuang; Yuan-Chin Amy Lee; Stefania Boccia; Hermann Brenner; Gabriela Cadoni; Luigino Dal Maso; Carlo La Vecchia; Philip Lazarus; Fabio Levi; Keitaro Matsuo; Hal Morgenstern; Heiko Müller; Joshua Muscat; Andrew F Olshan; Mark P Purdue; Diego Serraino; Thomas L Vaughan; Zuo-Feng Zhang; Paolo Boffetta; Mia Hashibe; Stephen M Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-12-05       Impact factor: 4.254

Review 3.  Regulation of adipocytokines and insulin resistance.

Authors:  M Fasshauer; R Paschke
Journal:  Diabetologia       Date:  2003-11-06       Impact factor: 10.122

Review 4.  A meta-analysis of short-term outcomes of patients with type 2 diabetes mellitus and BMI ≤ 35 kg/m2 undergoing Roux-en-Y gastric bypass.

Authors:  Wen-Sheng Rao; Cheng-Xiang Shan; Wei Zhang; Dao-Zhen Jiang; Ming Qiu
Journal:  World J Surg       Date:  2015-01       Impact factor: 3.352

5.  The Genetic Basis of Type 2 Diabetes.

Authors:  Swapan Kumar Das; Steven C Elbein
Journal:  Cellscience       Date:  2006-04-30

Review 6.  Beta cell mass in diabetes: a realistic therapeutic target?

Authors:  J J Meier
Journal:  Diabetologia       Date:  2008-03-04       Impact factor: 10.122

7.  The MOR-1 opioid receptor regulates glucose homeostasis by modulating insulin secretion.

Authors:  Ting Wen; Bonnie Peng; John E Pintar
Journal:  Mol Endocrinol       Date:  2009-02-12

8.  A novel functional polymorphism (-336A/G) in the promoter of the partitioning-defective protein-6alpha gene is associated with increased glucose tolerance and lower concentrations of serum non-esterified fatty acids.

Authors:  P Weyrich; R Lammers; A Fritsche; F Machicao; H-U Häring; N Stefan
Journal:  Diabetologia       Date:  2005-03-03       Impact factor: 10.122

Review 9.  Public health genomics and genetic test evaluation: the challenge of conducting behavioural research on the utility of lifestyle-genetic tests.

Authors:  Saskia C Sanderson; Jane Wardle; Steve E Humphries
Journal:  J Nutrigenet Nutrigenomics       Date:  2008-08-06

10.  Loss of beta cell function as fasting glucose increases in the non-diabetic range.

Authors:  I F Godsland; J A R Jeffs; D G Johnston
Journal:  Diabetologia       Date:  2004-07-13       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.